evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

9 questions · 12 findings · 6 reviews · Vascular

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 3 · 25%GRADE not reported 0 · 0%Very low 1 · 8.3%Low 4 · 33.3%Moderate 4 · 33.3%High 0 · 0%

Low molecular weight heparin and idraparinux vs usual care

Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis

The review found no eligible studies for this question.

2 findings from 1 review

Low molecular weight heparin vs active control

Major bleeding · ambulatory cancer patients receiving chemotherapy

The review found no eligible studies for this question.

3 findings from 1 review

Low molecular weight heparin vs no prophylaxis

All adverse effects, including allergies at injection site, minor and major bleeding, others ( · adults undergoing KA

Low‐molecular‐weight heparin showed no clear difference in all adverse effects, including allergies at injection site, minor… compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Subcutaneous unfractionated heparin vs low molecular weight heparin

Major bleedingd (3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE

Subcutaneous unfractionated heparin showed no clear difference in major bleedingd (3 months) compared with low molecular weight heparin (low certainty).

1 finding from 1 review

Low molecular weight heparin vs vitamin K antagonist (VKA)

Major bleeding · patients with symptomatic VTE requiring long term treatment (3 months) for symptomatic VTE

LMWH may leads to lower incidence of major bleeding (treatment duration 3 months) compared with VKA (low certainty).

1 finding from 1 review